{"id":"combo","rwe":[{"pmid":"41900452","year":"2026","title":"Advancing HIV Diagnostics: Comparative Evaluation of Multisure HIV-1/2 Rapid Confirmatory Test Against Geenius and Traditional Reference Assays Within a CDC-Aligned Diagnostic Framework.","finding":"","journal":"Microorganisms","studyType":"Clinical Study"},{"pmid":"41897563","year":"2026","title":"Evaluation of Flu A/B, SARS-CoV-2, and RSV Antigen Combo Rapid Test in Hospitalized Children Under Two Years of Age.","finding":"","journal":"Diagnostics (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"41895288","year":"2026","title":"Immunogenic tumor cell death and T-cell-derived IFN-γ elicit tumoricidal macrophages to potentiate OX40 immunotherapy.","finding":"","journal":"Cell reports. Medicine","studyType":"Clinical Study"},{"pmid":"41891001","year":"2026","title":"Prenatal exposure to SARS-CoV-2, early relational health, and child socio-emotional functioning in the first 6 months.","finding":"","journal":"medRxiv : the preprint server for health sciences","studyType":"Clinical Study"},{"pmid":"41867287","year":"2026","title":"Comparative Analysis of Radiation Dose in Advanced X-Ray Mammographic Modalities and Evaluation of Potential Influencing Factors.","finding":"","journal":"The Indian journal of radiology & imaging","studyType":"Clinical Study"}],"_fda":{"id":"292fb349-6c9d-d1dd-e063-6394a90a5ed9","set_id":"7aff8c66-e758-438a-872d-804a35bb372a","openfda":{"upc":["0731477391932"],"rxcui":["211365","259090"],"spl_id":["292fb349-6c9d-d1dd-e063-6394a90a5ed9"],"brand_name":["DermacinRx Surgical ComboPak"],"spl_set_id":["7aff8c66-e758-438a-872d-804a35bb372a"],"package_ndc":["59088-334-00","0116-1061-08","59088-333-08"],"product_ndc":["59088-334"],"generic_name":["CHLORHEXIDINE GLUCONATE SURGICAL COMBO KIT"],"product_type":["HUMAN PRESCRIPTION DRUG"],"manufacturer_name":["PureTek Corporation"],"is_original_packager":[true]},"purpose":["Purpose Antiseptic",""],"version":"8","warnings":["Warnings For external use only Do not use if you are allergic to chlorhexidine gluconate or any other ingredients in contact with meninges in the genital area as a preoperative skin preparation of the head or face When using this product keep out of eyes, ears, and mouth. May cause serious and permanent eye injury if placed or kept in the eye during surgical procedures or may cause deafness when instilled in the middle ear through perforated eardrums. if solution should contact these areas, rinse out promptly and thoroughly with water wounds which involve more than the superficial layers of the skin should not be routinely treated repeated general skin cleansing of large body areas should not be done except when the underlying condition makes it necessary to reduce the bacterial population of skin Stop use and ask a doctor if irritation, sensitization or allergic reaction occurs. These may be signs of a serious condition. Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.","Warnings For external use only Do not use on ■ deep or puncture wounds ■ animal bites ■ serious burns When using this product ■ do not get into eyes Stop use and ask a doctor if ■ condition worsens ■ symptoms last more than 7 days or clear up and occur again within a few days Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away."],"effective_time":"20241213","active_ingredient":["Active ingredient Chlorhexidine Gluconate 4% solution Purpose Antiseptic","Active ingredient Dimethicone 5.0%"],"inactive_ingredient":["Inactive ingredients cocamide DEA, fragrance, glucono-delta-lactone, hydroxyethylcellulose, isopropyl alcohol, lauramine oxide, PEG-75 lanolin, purified water, tridecyl alcohol","Inactive ingredients Aleurites moluccana seed oil, Aloe barbadensis ( Aloe vera ) leaf juice, butylene glycol, caprylyl glycol, Carthamus tinctorius (safflower) seed oil, cetyl alcohol, chlorphenesin, dimethicone crosspolymer, disodium EDTA, fragrance, glycerin, glyceryl stearate, DermacinRx Complex ® [consisting of: bisabolol, calcium pantothenate (vitamin B 5 ), Carthamus tinctorius (safflower) oleosomes, maltodextrin, niacinamide (vitamin B 3 ), pyridoxine HCl (vitamin B 6 ), silica, sodium ascorbyl phosphate (vitamin C), sodium starch octenylsuccinate, tocopheryl acetate (vitamin E), Zingiber officinale (ginger) root extract], PEG-100 stearate, pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate, phenoxyethanol, purified water, sodium hyaluronate, stearic acid, triethanolamine."],"storage_and_handling":["Other information store at 20-25ºC (68-77ºF) avoid excessive heat above 40ºC (104ºF)","Other information ■ protect from freezing ■ avoid excessive heat"],"indications_and_usage":["Uses surgical hand scrub: significantly reduces the number of microorganisms on the hands and forearms prior to surgery or patient care healthcare personnel handwash: helps reduce bacteria that potentially can cause disease patient preoperative skin preparation: for the preparation of the patient's skin prior to surgeryskin wound and general skin cleansing skin wound and general skin cleansing","Uses ■ for the treatment and/or prevention of diaper rash ■ temporarily protects and helps relieve chapped or cracked skin"],"spl_unclassified_section":["PART 1: Chlorhexidine Gluconate Drug Facts","PART 2: Skin Repair Complex Drug Facts","PART 3: Silicone Tape Uses • To be applied to wounds or scars as a protective silicone barrier. • As a dressing for abrasions, surgical wounds, donor sites, lacerations, ulcers, skin tears, superficial partial thickness burns, venous leg ulcers. • As a dressing/securement for IV related uses, pressure ulcers, skin care, and wound care Precautions • Do not use if you are allergic to silicone • Keep out of reach of children Directions for use • Apply tape to wound or scar as needed or as directed by your physician. Remove tape, wash area, and apply new tape at least every 24 hours."],"dosage_and_administration":["Directions use with care in premature infants and infants under 2 months of age. These products may cause irritation or chemical burns. Surgical hand scrub: wet hands and forearms with water scrub for 3 minutes with about 5 ml of product and a wet brush paying close attention to the nails, cuticles and interdigital spaces a separate nail cleaner may be used rinse thoroughly wash for an additional 3 minutes with 5 ml of product and rinse under running water dry thoroughly Healthcare personnel handwash: wet hands with water dispense about 5 ml of product into cupped hands and wash in a vigorous manner for 15 seconds rinse and dry thoroughly Patient preoperative skin preparation: apply product liberally to surgical site and swab for at least 2 minutes and dry with a sterile towel repeat procedure for an additional 2 minutes and dry with a sterile towel Skin wound and general skin cleaning: thoroughly rinse the area to be cleaned with water apply the minimum amount of product necessary to cover the skin or wound area and wash gently rinse again thoroughly","Directions ■ apply cream liberally as needed"],"spl_product_data_elements":["DermacinRx Surgical ComboPak Chlorhexidine Gluconate Surgical Combo Kit ANTISEPTIC SKIN CLEANSER Chlorhexidine Gluconate COCO DIETHANOLAMIDE HYDROXYETHYL CELLULOSE (2000 CPS AT 1%) ISOPROPYL ALCOHOL LAURAMINE OXIDE WATER TRIDECYL ALCOHOL GLUCONOLACTONE PEG-75 LANOLIN CHLORHEXIDINE GLUCONATE CHLORHEXIDINE Skin Repair Complex Dimethicone KUKUI NUT OIL ALOE VERA LEAF BUTYLENE GLYCOL CAPRYLYL GLYCOL SAFFLOWER OIL CETYL ALCOHOL CHLORPHENESIN DIMETHICONE/DIENE DIMETHICONE CROSSPOLYMER EDETATE DISODIUM GLYCERIN GLYCERYL MONOSTEARATE LEVOMENOL CALCIUM PANTOTHENATE CARTHAMUS TINCTORIUS SEED OLEOSOMES MALTODEXTRIN NIACINAMIDE PYRIDOXINE HYDROCHLORIDE SILICON DIOXIDE SODIUM ASCORBYL PHOSPHATE .ALPHA.-TOCOPHEROL ACETATE, DL- GINGER PEG-100 STEARATE PENTAERYTHRITOL TETRAKIS(3-(3,5-DI-TERT-BUTYL-4-HYDROXYPHENYL)PROPIONATE) PHENOXYETHANOL WATER HYALURONATE SODIUM STEARIC ACID TROLAMINE DIMETHICONE DIMETHICONE"],"package_label_principal_display_panel":["image description"]},"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"surgery or patient care","category":"indication"},{"label":"bacteria that potentially can cause disease","category":"indication"},{"label":"diaper rash","category":"indication"},{"label":"chapped or cracked skin","category":"indication"},{"label":"PureTek Corporation","category":"company"}],"phase":"marketed","safety":{"boxedWarnings":[],"commonSideEffects":[{"effect":"Infusion site pain","drugRate":"","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"","severity":"common","organSystem":""},{"effect":"Constipation","drugRate":"","severity":"common","organSystem":""},{"effect":"Dizziness","drugRate":"","severity":"common","organSystem":""},{"effect":"Infusion site extravasation","drugRate":"","severity":"common","organSystem":""},{"effect":"Vomiting","drugRate":"","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"","severity":"common","organSystem":""},{"effect":"Somnolence","drugRate":"","severity":"common","organSystem":""},{"effect":"Pruritis","drugRate":"2.5%","severity":"common","organSystem":""},{"effect":"Hyperhidrosis","drugRate":"2.5%","severity":"common","organSystem":""},{"effect":"Procedural nausea","drugRate":"2.5%","severity":"common","organSystem":""},{"effect":"Polyuria","drugRate":"2.5%","severity":"common","organSystem":""}],"seriousAdverseEvents":[{"effect":"Hepatotoxicity","drugRate":"","severity":"serious"},{"effect":"Cardiovascular Thrombotic Events","drugRate":"","severity":"serious"},{"effect":"Gastrointestinal Bleeding, Ulceration, and Perforation","drugRate":"","severity":"serious"},{"effect":"Hypertension","drugRate":"","severity":"serious"},{"effect":"Heart Failure and Edema","drugRate":"","severity":"serious"},{"effect":"Renal Toxicity and Hyperkalemia","drugRate":"","severity":"serious"},{"effect":"Hypersensitivity and Anaphylactic Reactions","drugRate":"","severity":"serious"},{"effect":"Exacerbation of Asthma Related to Aspirin Sensitivity","drugRate":"","severity":"serious"},{"effect":"Serious Skin Reactions","drugRate":"","severity":"serious"},{"effect":"Drug Rash with Eosinophilia and Systemic Symptoms (DRESS)","drugRate":"","severity":"serious"}]},"trials":[],"aliases":["Combination schedule"],"company":"PureTek Corporation","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=COMBO","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:14:40.369804+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:14:41.025164+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=COMBO","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:14:41.640618+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:14:39.123529+00:00"}},"allNames":"dermacinrx surgical combopak","offLabel":[],"synonyms":["DermacinRx Surgical ComboPak"],"timeline":[],"approvals":[],"brandName":"DermacinRx Surgical ComboPak","ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"DermacinRx Surgical ComboPak is a small molecule product that likely works by inhibiting bacterial growth and replication, as well as modulating the skin's natural barrier function to promote healing and protection."},"commercial":{},"references":[{"id":1,"url":"https://api.fda.gov/drug/label.json?search=openfda.generic_name:\"COMBO\"","fields":["mechanism","indications","adverse_reactions","contraindications","warnings","dosage"],"source":"OpenFDA Label"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=combo","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=combo","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-31T10:25:54.997792","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:14:44.386733+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"combo","indications":{"approved":[{"name":"surgery or patient care","source":"OpenFDA Label","regulator":"FDA"},{"name":"bacteria that potentially can cause disease","source":"OpenFDA Label","regulator":"FDA"},{"name":"diaper rash","source":"OpenFDA Label","regulator":"FDA"},{"name":"chapped or cracked skin","source":"OpenFDA Label","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05564377","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-04-07","conditions":["Advanced Malignant Solid Neoplasm","Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IV Breast Cancer AJCC v8","Locally Advanced Malignant Solid Neoplasm","Malignant Female Reproductive System Neoplasm","Metastatic HER2-Negative Breast Carcinoma","Metastatic Malignant Solid Neoplasm","Recurrent Endometrial Carcinoma","Recurrent Fallopian Tube Carcinoma","Recurrent Malignant Female Reproductive System Neoplasm","Recurrent Malignant Solid Neoplasm","Recurrent Ovarian Carcinoma","Recurrent Primary Peritoneal Carcinoma","Unresectable HER2-Negative Breast Carcinoma","Unresectable Malignant Solid Neoplasm"],"enrollment":2900,"completionDate":"2030-07-01"},{"nctId":"NCT05039177","phase":"PHASE1,PHASE2","title":"A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies","status":"COMPLETED","sponsor":"Erasca, Inc.","startDate":"2021-09-20","conditions":["Metastatic Colorectal Cancer","Metastatic Pancreatic Ductal Adenocarcinoma"],"enrollment":101,"completionDate":"2026-01-26"},{"nctId":"NCT06645886","phase":"PHASE1","title":"A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kumquat Biosciences Inc.","startDate":"2024-12-09","conditions":["Hematologic Malignancies","Adult"],"enrollment":13,"completionDate":"2027-03"},{"nctId":"NCT01577082","phase":"PHASE3","title":"Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2012-04-20","conditions":["Asthma"],"enrollment":542,"completionDate":"2012-11-29"},{"nctId":"NCT07154745","phase":"PHASE3","title":"A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2026-03-31","conditions":["Paroxysmal Nocturnal Hemoglobinuria"],"enrollment":35,"completionDate":"2031-09-23"},{"nctId":"NCT04143711","phase":"PHASE1,PHASE2","title":"Study of DF1001 in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Dragonfly Therapeutics","startDate":"2019-11-11","conditions":["Solid Tumor, Adult"],"enrollment":270,"completionDate":"2025-12-05"},{"nctId":"NCT07175155","phase":"NA","title":"Combination of COMBO Endoscopy Oropharyngeal Airway and HFNC Oxygenation in Sedated Gastrointestinal Endoscopy for Morbidly Obese Patients","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2025-10-24","conditions":["Hypoxemia","Esophageal Cancer","Morbidly Obese Patients","Gastric Cancer"],"enrollment":410,"completionDate":"2027-08-20"},{"nctId":"NCT06083857","phase":"PHASE1,PHASE2","title":"PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-06-18","conditions":["Non-small Cell Lung Cancer"],"enrollment":3,"completionDate":"2027-12-31"},{"nctId":"NCT06548230","phase":"PHASE1,PHASE2","title":"A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-03-05","conditions":["Myelodysplastic Syndrome(MDS)","Acute Myelogenous Leukemia (AML)"],"enrollment":40,"completionDate":"2029-12-01"},{"nctId":"NCT06130995","phase":"PHASE1","title":"Relugolix + Enzalutamide Study in High-Risk Prostate Cancer","status":"RECRUITING","sponsor":"University of Oklahoma","startDate":"2024-12-26","conditions":["Androgen Deprivation Therapy","Locally Advanced Prostate Cancer"],"enrollment":46,"completionDate":"2030-01"},{"nctId":"NCT06994806","phase":"PHASE1","title":"A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies","status":"RECRUITING","sponsor":"Kumquat Biosciences Inc.","startDate":"2025-06-24","conditions":["Solid Tumor Malignancies"],"enrollment":84,"completionDate":"2028-05-31"},{"nctId":"NCT05125016","phase":"PHASE1,PHASE2","title":"A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2021-11-30","conditions":["Metastatic Castration-resistant Prostate Cancer"],"enrollment":370,"completionDate":"2027-01-14"},{"nctId":"NCT01909453","phase":"PHASE3","title":"Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-09-12","conditions":["Melanoma"],"enrollment":921,"completionDate":"2024-09-03"},{"nctId":"NCT07432594","phase":"PHASE2","title":"Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-03-01","conditions":["High-grade Serous Ovarian Cancer (HGSOC)","Fallopian Tube Cancers","Primary Peritoneal Cancer"],"enrollment":82,"completionDate":"2027-06-30"},{"nctId":"NCT07063290","phase":"PHASE2","title":"COMBO Endoscopy Oropharyngeal Airway in Sedated Fiberoptic Bronchoscopy for Patients: A Simon Two-Stage Trial","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2025-06-23","conditions":["Pulmonary Infection","Pulmonary Nodule","Endotracheal Tumour","Bronchiectasis"],"enrollment":104,"completionDate":"2025-09-18"},{"nctId":"NCT05753722","phase":"PHASE1","title":"A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies","status":"RECRUITING","sponsor":"Incendia Therapeutics","startDate":"2023-03-03","conditions":["Advanced or Metastatic Solid Tumors","Non Small Cell Lung Cancer","NSCLC"],"enrollment":270,"completionDate":"2027-09-30"},{"nctId":"NCT07382726","phase":"PHASE1","title":"Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A Trial","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-07-01","conditions":["Non-small Cell Lung Cancer"],"enrollment":18,"completionDate":"2029-12-24"},{"nctId":"NCT07028931","phase":"NA","title":"Effects of Visualization Technique Compared to Combined Stretching Protocol in Racquet Sports.","status":"COMPLETED","sponsor":"Riphah International University","startDate":"2025-01-28","conditions":["Sport Injury"],"enrollment":52,"completionDate":"2025-04-23"},{"nctId":"NCT04868877","phase":"PHASE1,PHASE2","title":"Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merus B.V.","startDate":"2021-04-28","conditions":["Non-Small Cell Lung Cancer Metastatic","Gastric Cancer","Esophageal Squamous Cell Carcinoma","Head and Neck Squamous Cell Carcinoma","Colorectal Cancer"],"enrollment":194,"completionDate":"2027-03"},{"nctId":"NCT07415005","phase":"PHASE2","title":"Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-08-31","conditions":["Advanced Non-Small Cell Lung Cancer"],"enrollment":30,"completionDate":"2030-07-22"},{"nctId":"NCT07130695","phase":"PHASE1","title":"Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation","status":"RECRUITING","sponsor":"Virginia Commonwealth University","startDate":"2026-02-02","conditions":["Acute Myeloid Leukemia"],"enrollment":15,"completionDate":"2030-10-31"},{"nctId":"NCT06507306","phase":"PHASE1","title":"A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies","status":"RECRUITING","sponsor":"Kumquat Biosciences Inc.","startDate":"2024-06-03","conditions":["Solid Tumor, Adult"],"enrollment":100,"completionDate":"2027-01-31"},{"nctId":"NCT07376837","phase":"NA","title":"Radiofrequency Ablation for Curative Treatment of Small Low-Risk Papillary Thyroid Cancer: Pilot Study","status":"NOT_YET_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2026-02-05","conditions":["Thyroid Papillary Carcinoma"],"enrollment":30,"completionDate":"2027-07-01"},{"nctId":"NCT07359053","phase":"PHASE2","title":"MAGNATE-S: Paclitaxel Polymer Micelles Combo in Advanced Sarcoma","status":"RECRUITING","sponsor":"Shanghai 6th People's Hospital","startDate":"2025-12-25","conditions":["Sarcoma"],"enrollment":46,"completionDate":"2028-09-30"},{"nctId":"NCT04413123","phase":"PHASE2","title":"Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bradley A. McGregor, MD","startDate":"2020-11-05","conditions":["Papillary Renal Cell Carcinoma","Unclassified Renal Cell Carcinoma","Translocation Renal Cell Carcinoma","Chromophobe Renal Cell Carcinoma","Collecting Duct Renal Cell Carcinoma","Renal Cell Carcinoma","Unresectable Advanced Renal Cell Carcinoma","Metastatic Ncc Renal Cell Carcinoma"],"enrollment":60,"completionDate":"2026-12-20"},{"nctId":"NCT07235007","phase":"NA","title":"Repeated Endobiliary Radiofrequency Ablation Plus Durvalumab, Gemcitabine, and Cisplatin for Unresectable Extrahepatic Cholangiocarcinoma","status":"RECRUITING","sponsor":"Aichi Medical University","startDate":"2025-11-20","conditions":["Extrahepatic Cholangiocarcinoma"],"enrollment":120,"completionDate":"2030-12-31"},{"nctId":"NCT05661084","phase":"NA","title":"Non-invasive Brain Stimulation for Cognitive and Motor Dysfunction in Dementia","status":"RECRUITING","sponsor":"Hebrew SeniorLife","startDate":"2023-01-24","conditions":["Dementia","Memory Loss","Alzheimer Disease","Executive Dysfunction","Mobility Limitation"],"enrollment":144,"completionDate":"2027-08-31"},{"nctId":"NCT03923270","phase":"PHASE1","title":"Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-06-06","conditions":["Small Cell Lung Cancer Extensive Stage","Small-cell Lung Cancer"],"enrollment":25,"completionDate":"2026-12"},{"nctId":"NCT01995058","phase":"PHASE2","title":"Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC","status":"TERMINATED","sponsor":"Exelixis","startDate":"2014-02","conditions":["Prostate Cancer","Castration Resistant Prostate Cancer","Prostatic Neoplasms"],"enrollment":54,"completionDate":"2014-11"},{"nctId":"NCT07190131","phase":"","title":"Evaluation of COVID-19 and Flu A/B 3 in 1 Combo Rapid Test","status":"COMPLETED","sponsor":"iHealth Labs inc","startDate":"2024-11-12","conditions":["COVID - 19","Influenza A","Influenza B"],"enrollment":588,"completionDate":"2025-12-12"},{"nctId":"NCT05544929","phase":"PHASE1","title":"A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-10-26","conditions":["Carcinoma, Non-Small-Cell Lung","Cutaneous Melanoma","Carcinoma, Renal Cell","Carcinoma, Ovarian Epithelial","Nasopharyngeal Carcinoma","Carcinoma, Thymic","Anal Cancer","Mesothelioma","Esophagogastric Cancer","High Microsatellite Instability Colorectal Carcinoma","Squamous Cell Carcinoma of Head and Neck","Triple Negative Breast Neoplasms"],"enrollment":126,"completionDate":"2027-09-01"},{"nctId":"NCT07187778","phase":"PHASE2","title":"Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-12-19","conditions":["Clear Cell Renal Cell Carcinoma"],"enrollment":10,"completionDate":"2029-07-19"},{"nctId":"NCT06603181","phase":"NA","title":"Effect of Extracorporeal Shock Wave Therapy (ESWT) and Phonophoresis Treatment in Patients With Lateral Epicondylitis","status":"COMPLETED","sponsor":"Kirsehir Ahi Evran Universitesi","startDate":"2024-09-25","conditions":["Lateral Epicondylitis","Extracorporeal Shock Wave Therapy","Phonophoresis"],"enrollment":60,"completionDate":"2025-04-30"},{"nctId":"NCT05490134","phase":"EARLY_PHASE1","title":"RM1 Project 1 - tAN Naloxone","status":"RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2023-03-22","conditions":["Analgesia"],"enrollment":136,"completionDate":"2027-10-01"},{"nctId":"NCT06972992","phase":"PHASE1","title":"A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Combination With Semaglutide","status":"COMPLETED","sponsor":"Ascletis Pharma (China) Co., Limited","startDate":"2025-04-18","conditions":["Chronic Weight Management"],"enrollment":28,"completionDate":"2025-09-22"},{"nctId":"NCT05487664","phase":"NA","title":"RM1 Project 2 - tAN fMRI","status":"RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2023-03-17","conditions":["Auricular Stimulation"],"enrollment":96,"completionDate":"2027-10-01"},{"nctId":"NCT06079775","phase":"PHASE1","title":"P1, DDI & MAD PK and Safety Study of Xeruborbactam Oral Prodrug in Combo With Ceftibuten in Healthy Participants","status":"COMPLETED","sponsor":"Qpex Biopharma, Inc.","startDate":"2024-01-30","conditions":["Bacterial Infections"],"enrollment":53,"completionDate":"2025-01-05"},{"nctId":"NCT06492538","phase":"","title":"Biometric Changes After Intervention of Anterior Chamber Angle : an Observational Study","status":"RECRUITING","sponsor":"Zhongshan Ophthalmic Center, Sun Yat-sen University","startDate":"2023-12-01","conditions":["Angle-closure Glaucoma","Minimally Invasive Glaucoma Surgery","Goniosynechialysis","Goniotomy","Glaucoma"],"enrollment":300,"completionDate":"2025-12-30"},{"nctId":"NCT07260305","phase":"PHASE1","title":"A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolimab in Advanced or Metastatic Solid Tumor Patients","status":"RECRUITING","sponsor":"Kangabio AUSTRALIA LTD PTY","startDate":"2024-11-27","conditions":["Advanced or Metastatic Solid Tumors"],"enrollment":57,"completionDate":"2027-03-30"},{"nctId":"NCT05723107","phase":"PHASE1","title":"EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2023-03-31","conditions":["Pancreatic Cancer"],"enrollment":15,"completionDate":"2028-03"},{"nctId":"NCT07206498","phase":"PHASE1,PHASE2","title":"A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC","status":"RECRUITING","sponsor":"Wayshine Biopharm, Inc.","startDate":"2025-10-17","conditions":["Non Small Cell Lung Cancer (NSCLC)"],"enrollment":48,"completionDate":"2029-10-14"},{"nctId":"NCT06626516","phase":"PHASE1,PHASE2","title":"Tebentafusp-tebn With LDT in Metastatic UM","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2025-10-15","conditions":["Metastatic Uveal Melanoma"],"enrollment":109,"completionDate":"2032-08"},{"nctId":"NCT07095868","phase":"PHASE1,PHASE2","title":"Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors","status":"RECRUITING","sponsor":"Everest Medicines (Beijing) Co., Ltd.","startDate":"2025-11-17","conditions":["Selected Types of Solid Tumor"],"enrollment":94,"completionDate":"2031-11"},{"nctId":"NCT06117891","phase":"","title":"An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery","status":"RECRUITING","sponsor":"Bayer","startDate":"2023-11-27","conditions":["Unresectable Hepatocellular Carcinoma"],"enrollment":300,"completionDate":"2027-02-01"},{"nctId":"NCT05839951","phase":"","title":"An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions","status":"COMPLETED","sponsor":"Bayer","startDate":"2023-04-24","conditions":["Metastatic Colorectal Cancer (mCRC)"],"enrollment":818,"completionDate":"2025-04-30"},{"nctId":"NCT06246110","phase":"PHASE2","title":"A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC","status":"RECRUITING","sponsor":"Eikon Therapeutics","startDate":"2024-02-06","conditions":["NSCLC"],"enrollment":70,"completionDate":"2027-12"},{"nctId":"NCT06697301","phase":"PHASE2,PHASE3","title":"Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.","status":"RECRUITING","sponsor":"Eikon Therapeutics","startDate":"2025-05-22","conditions":["Advanced Melanoma"],"enrollment":740,"completionDate":"2040-12"},{"nctId":"NCT06698250","phase":"PHASE2","title":"Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)","status":"RECRUITING","sponsor":"Anwaar Saeed","startDate":"2024-12-18","conditions":["Hepatocellular Carcinoma"],"enrollment":40,"completionDate":"2027-04-30"},{"nctId":"NCT04543188","phase":"PHASE1","title":"A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement","status":"TERMINATED","sponsor":"Pfizer","startDate":"2021-01-08","conditions":["Malignant Melanoma","Carcinoma, Non-Small-Cell Lung","Brain Neoplasms, Primary","Brain Neoplasms","Malignant Neoplasms"],"enrollment":65,"completionDate":"2024-03-20"},{"nctId":"NCT05081219","phase":"PHASE2","title":"SNIFF - Combo INI+EMPA Trial","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2021-09-14","conditions":["Mild Cognitive Impairment","Cognitive Impairment","Alzheimer Disease"],"enrollment":47,"completionDate":"2024-09-17"},{"nctId":"NCT05639751","phase":"PHASE1","title":"PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation","status":"COMPLETED","sponsor":"Prelude Therapeutics","startDate":"2023-05-02","conditions":["Advanced Solid Tumor","Metastatic Solid Tumor","Non-small Cell Lung Cancers","SMARCA4 Gene Mutation"],"enrollment":135,"completionDate":"2025-10-01"},{"nctId":"NCT06280716","phase":"PHASE3","title":"A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-04-24","conditions":["Atopic Dermatitis"],"enrollment":301,"completionDate":"2026-08"},{"nctId":"NCT06564792","phase":"NA","title":"Contingency Management in HIV Care for Both Stimulant Use & ART Adherence","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2023-09-15","conditions":["Stimulant Use (Diagnosis)","Hiv"],"enrollment":37,"completionDate":"2025-10-01"},{"nctId":"NCT06359691","phase":"NA","title":"Multi-ethnic Multi-level Strategies and Behavioral Economics to Eliminate Hypertension Disparities in Los Angeles County","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2024-08-08","conditions":["Hypertension"],"enrollment":540,"completionDate":"2027-10"},{"nctId":"NCT06796764","phase":"NA","title":"COMBO Endoscopy Oropharyngeal Airway Reduces Hypoxia During Sedated Gastrointestinal Endoscopy in Obese Patients: A Multicenter, Randomized, Controlled Clinical Trial","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2025-04-11","conditions":["Hypoxia","Esophageal Cancer","Gastric Cancer"],"enrollment":580,"completionDate":"2025-12-04"},{"nctId":"NCT05318573","phase":"PHASE2","title":"A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fujifilm Pharmaceuticals U.S.A., Inc.","startDate":"2022-06-01","conditions":["Advanced Urothelial Carcinoma","Advanced Non Small Cell Lung Cancer"],"enrollment":120,"completionDate":"2029-11"},{"nctId":"NCT05816785","phase":"EARLY_PHASE1","title":"Pilot Study of Imatinib Cetuximab Combo for H & N Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2023-04-18","conditions":["Head and Neck Cancer","Squamous Cell Carcinoma of Head and Neck"],"enrollment":15,"completionDate":"2026-04-30"},{"nctId":"NCT06433947","phase":"PHASE1","title":"Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Opna Bio LLC","startDate":"2024-08-22","conditions":["Relapsed Multiple Myeloma","Refractory Multiple Myeloma"],"enrollment":130,"completionDate":"2026-07"},{"nctId":"NCT04795934","phase":"NA","title":"Multicenter Single-Blind RCT of CTIF Versus LNF For Treatment of GERD in Patients Requiring Hiatal Hernia Repair","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2021-01-26","conditions":["GERD","Hiatal Hernia"],"enrollment":142,"completionDate":"2030-01"},{"nctId":"NCT06597058","phase":"PHASE2","title":"Phase 2 Estimation Study of Fixed Dose Drugs Combination Type of Polypill","status":"ACTIVE_NOT_RECRUITING","sponsor":"Noah Pharmaceuticals, Inc.","startDate":"2024-10-16","conditions":["Alzheimer Disease"],"enrollment":103,"completionDate":"2026-02-15"},{"nctId":"NCT04306900","phase":"PHASE1","title":"TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers","status":"COMPLETED","sponsor":"Trishula Therapeutics, Inc.","startDate":"2020-03-30","conditions":["Solid Tumor, Adult"],"enrollment":185,"completionDate":"2024-03-27"},{"nctId":"NCT04627064","phase":"PHASE1","title":"ABEMA Alone or in COMBO With MK-6482","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-12-31","conditions":["Clear Cell Renal Cell Carcinoma"],"enrollment":11,"completionDate":"2024-08-04"},{"nctId":"NCT06373679","phase":"NA","title":"Switch or Quit R01","status":"RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2024-07-10","conditions":["Cigarette Smoking","Smoking Behaviors"],"enrollment":225,"completionDate":"2027-05-01"},{"nctId":"NCT02358031","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-03-19","conditions":["Recurrent Head and Neck Cancer","Metastatic Head and Neck Cancer"],"enrollment":882,"completionDate":"2023-07-19"},{"nctId":"NCT06903208","phase":"NA","title":"RFA for Superficial Lipomas","status":"RECRUITING","sponsor":"Columbia University","startDate":"2025-04-02","conditions":["Lipoma"],"enrollment":10,"completionDate":"2026-12"},{"nctId":"NCT06720987","phase":"PHASE1","title":"A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies","status":"RECRUITING","sponsor":"Kumquat Biosciences Inc.","startDate":"2025-02-04","conditions":["KRAS G12C Mutation","KRAS G12S Mutation","Solid Tumor Malignancies","CRC (Colorectal Cancer)"],"enrollment":128,"completionDate":"2030-06-30"},{"nctId":"NCT05815758","phase":"PHASE3","title":"Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2023-04-20","conditions":["Allergic Conjunctivitis"],"enrollment":512,"completionDate":"2023-09-18"},{"nctId":"NCT07011511","phase":"PHASE1","title":"Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of LAI MMV055 Alone and in Combination With MMV371 in Healthy Participants","status":"RECRUITING","sponsor":"Medicines for Malaria Venture","startDate":"2025-06-30","conditions":["Malaria, Falciparum"],"enrollment":72,"completionDate":"2027-12-02"},{"nctId":"NCT06903312","phase":"PHASE4","title":"Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations.","status":"RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2025-06-15","conditions":["Renal Cell Cancer","Kidney Neoplasm","Immunotherapy","Kidney Cancer","Surgery Programmed","Radiotherapy"],"enrollment":409,"completionDate":"2028-04-01"},{"nctId":"NCT06081647","phase":"NA","title":"The Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway in Gastrointestinal Endoscopy Procedure","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2023-12-27","conditions":["Hypoxia","Gastric Polyp","Colon Cancer","Esophageal Cancer"],"enrollment":1200,"completionDate":"2025-12-27"},{"nctId":"NCT06812403","phase":"PHASE2","title":"Combination COMBO Endoscopy Oropharyngeal Airway With High-Flow Nasal Cannula Oxygenation in Sedated Gastrointestinal Endoscopy for Obese Patients","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2025-02-04","conditions":["Hypoxia","Esophageal Cancer","Gastric Cancer","Polyp of Colon"],"enrollment":50,"completionDate":"2025-06-04"},{"nctId":"NCT04132557","phase":"","title":"A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-10-09","conditions":["Attention Deficit Disorder With Hyperactivity"],"enrollment":430000,"completionDate":"2019-10-25"},{"nctId":"NCT07012772","phase":"PHASE2","title":"COMBO Endoscopy Oropharyngeal Airway in Sedated Endoscopic Retrograde Cholangiopancreatography for Patients","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2025-06-12","conditions":["Choledocholithiasis With Cholecystitis With Obstruction","Obstructive Jaundice","Pancreatitis","Cholelithiasis"],"enrollment":50,"completionDate":"2025-12-31"},{"nctId":"NCT04673617","phase":"PHASE1,PHASE2","title":"AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Artiva Biotherapeutics, Inc.","startDate":"2021-03-29","conditions":["Non Hodgkin Lymphoma"],"enrollment":45,"completionDate":"2025-12-31"},{"nctId":"NCT05609097","phase":"NA","title":"PRIME HFrEF: Novel Exercise for Older Patients With Heart Failure With Reduced Ejection Fraction","status":"RECRUITING","sponsor":"University of Virginia","startDate":"2023-04-14","conditions":["Heart Failure With Reduced Ejection Fraction"],"enrollment":92,"completionDate":"2028-06-30"},{"nctId":"NCT03782415","phase":"PHASE1,PHASE2","title":"Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma","status":"COMPLETED","sponsor":"MediciNova","startDate":"2018-12-29","conditions":["Glioblastoma","Recurrent Glioblastoma","GBM","Newly Diagnosed Glioblastoma"],"enrollment":64,"completionDate":"2023-08-07"},{"nctId":"NCT06804876","phase":"PHASE2","title":"COMBO Endoscopy Oropharyngeal Airway in Sedated Gastrointestinal Endoscopy for Obese Patients","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2025-02-04","conditions":["Hypoxia","Esophageal Cancer","Colon Cancer","Gastric Cancer"],"enrollment":107,"completionDate":"2025-03-26"},{"nctId":"NCT04158154","phase":"NA","title":"Transforming Hypertension Treatment in Nigeria Using a Type II Hybrid, Interrupted Time Series Design","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2020-02-01","conditions":["Hypertension"],"enrollment":21922,"completionDate":"2023-12-31"},{"nctId":"NCT06112067","phase":"NA","title":"Efficacy and Safety of Combo-stim Deep Brain Stimulation for Treatment-refractory Mental Disorders","status":"RECRUITING","sponsor":"Shanghai Mental Health Center","startDate":"2023-10-16","conditions":["Deep Brain Stimulation"],"enrollment":18,"completionDate":"2026-08"},{"nctId":"NCT06453317","phase":"PHASE2","title":"Comparison of Ustekinumab, Infliximab and Combination Therapy in Moderately to Severely Active Ulcerative Colitis","status":"RECRUITING","sponsor":"Medical University of Lodz","startDate":"2025-02-17","conditions":["Ulcerative Colitis","Inflammatory Bowel Diseases"],"enrollment":172,"completionDate":"2028-06-30"},{"nctId":"NCT05555342","phase":"EARLY_PHASE1","title":"A Novel Method for Treating Lung Met w/Combo of Electric Fields & Rad Therapy: A Single-Arm","status":"COMPLETED","sponsor":"University of California, Irvine","startDate":"2023-01-03","conditions":["Lung Tumor","Metastatic Cancer"],"enrollment":6,"completionDate":"2024-10-27"},{"nctId":"NCT03618641","phase":"PHASE2","title":"CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease","status":"COMPLETED","sponsor":"Diwakar Davar","startDate":"2018-08-08","conditions":["Melanoma","Lymph Node Cancer"],"enrollment":34,"completionDate":"2023-12-31"},{"nctId":"NCT03189173","phase":"PHASE2","title":"Combined Upper-airway and Breathing Control Therapies for Obstructive Sleep Apnea","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2017-09-06","conditions":["Obstructive Sleep Apnea"],"enrollment":41,"completionDate":"2023-05-01"},{"nctId":"NCT05997095","phase":"NA","title":"Post-operative Electrical Muscle Stimulation to Stimulate Muscle Protein Synthesis in Humans","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Nottingham","startDate":"2023-05-22","conditions":["Skeletal Muscle Atrophy"],"enrollment":10,"completionDate":"2025-12-28"},{"nctId":"NCT06929650","phase":"NA","title":"The Safety and Feasibility of Radiofrequency Ablation to Treat Low-risk Thyroid Cancer","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2023-04-20","conditions":["Thyroid Nodule","Thyroid Cancer"],"enrollment":40,"completionDate":"2025-12-31"},{"nctId":"NCT05674526","phase":"PHASE1","title":"A Phase 1b Study of WU-NK-101 in Combination With Cetuximab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Wugen, Inc.","startDate":"2024-05-21","conditions":["Colorectal Cancer Metastatic","Squamous Cell Carcinoma of Head and Neck"],"enrollment":30,"completionDate":"2026-06-01"},{"nctId":"NCT06928129","phase":"NA","title":"Clinical Feasibility of the BinaxNOW™ COVID-19/Flu A&B Combo in the Southern Hemisphere","status":"NOT_YET_RECRUITING","sponsor":"Abbott Rapid Dx","startDate":"2025-06-30","conditions":["Influenza Type A","Influenza Type B","COVID-19"],"enrollment":700,"completionDate":"2025-11-01"},{"nctId":"NCT05423691","phase":"PHASE1","title":"Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs","status":"RECRUITING","sponsor":"Cellenkos, Inc.","startDate":"2022-12-27","conditions":["Myelofibrosis"],"enrollment":24,"completionDate":"2026-12-30"},{"nctId":"NCT06693323","phase":"PHASE2","title":"Single-Center Eval of Clinical & Radiological Benefit AHCC in Combo W/ SOC Tx for HPV+ Pts W/ HNSCC","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2024-12-04","conditions":["HNSCC","Head and Neck Squamous Cell Carcinoma"],"enrollment":34,"completionDate":"2027-12"},{"nctId":"NCT05511298","phase":"","title":"Empowering Students Project","status":"RECRUITING","sponsor":"University of Texas at Austin","startDate":"2021-05-03","conditions":["Relationship, Social"],"enrollment":1332,"completionDate":"2025-09-29"},{"nctId":"NCT04971343","phase":"","title":"Access HIV Ag/Ab Combo Assay - European Union (EU) Clinical Trial Protocol","status":"COMPLETED","sponsor":"Beckman Coulter, Inc.","startDate":"2019-12-04","conditions":["HIV I Infection","HIV-2 Infection"],"enrollment":8650,"completionDate":"2022-09-23"},{"nctId":"NCT06817551","phase":"PHASE4","title":"Comparison of Outcomes of Management of Bowel Obstruction Pilot Study","status":"ENROLLING_BY_INVITATION","sponsor":"University of Washington","startDate":"2025-03-01","conditions":["Adhesive Small Bowel Obstruction"],"enrollment":10,"completionDate":"2026-03"},{"nctId":"NCT06059443","phase":"NA","title":"mLab App Plus: A Randomized Controlled Trial of a Mobile Health (mHealth) Intervention","status":"COMPLETED","sponsor":"Columbia University","startDate":"2023-10-17","conditions":["HIV Infections","Sexually Transmitted Diseases, Viral","Syphilis"],"enrollment":40,"completionDate":"2024-06-21"},{"nctId":"NCT05036291","phase":"PHASE1","title":"A Study of NB004 as Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Ningbo Newbay Technology Development Co., Ltd","startDate":"2021-10-01","conditions":["Advanced Solid Tumor"],"enrollment":120,"completionDate":"2026-09-01"},{"nctId":"NCT04116203","phase":"PHASE1","title":"Dietary Fish Oil Intervention in Polycystic Ovary Syndrome (PCOS)","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2016-06-30","conditions":["Polycystic Ovary Syndrome","Lipid Metabolism Disorders"],"enrollment":52,"completionDate":"2020-11-12"},{"nctId":"NCT04465487","phase":"PHASE1","title":"Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies","status":"TERMINATED","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-10-05","conditions":["Squamous Cell Carcinoma of Head and Neck"],"enrollment":38,"completionDate":"2025-02-07"},{"nctId":"NCT04263051","phase":"PHASE2","title":"Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2020-09-09","conditions":["Advanced Non-small Cell Lung Cancer"],"enrollment":60,"completionDate":"2024-11-28"},{"nctId":"NCT05345015","phase":"NA","title":"High Frequency RF Current Effects on Muscle Pain and Function","status":"RECRUITING","sponsor":"Aristotle University Of Thessaloniki","startDate":"2022-04-30","conditions":["Transcutaneous Electric Nerve Stimulation","Chronic Low-back Pain","Hamstring Injury","Muscle; Injury, Quadriceps (Thigh)","Physical Therapy","Calf Muscle Pulled"],"enrollment":160,"completionDate":"2026-12-31"},{"nctId":"NCT06522919","phase":"PHASE2","title":"Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2025-01-07","conditions":["Colorectal Cancer Metastatic","Microsatellite Stable Colorectal Carcinoma","Refractory Mismatch-repair-proficient (pMMR) Metastatic Colorectal Cancer"],"enrollment":36,"completionDate":"2026-09-01"},{"nctId":"NCT06186414","phase":"PHASE1","title":"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC","status":"RECRUITING","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2024-01-23","conditions":["Non-Muscle-Invasive Bladder Cancer (NMIBC)"],"enrollment":152,"completionDate":"2030-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"RXCUI":"211365,259090","SPL_ID":"292fb349-6c9d-d1dd-e063-6394a90a5ed9"},"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"PureTek Corporation","relationship":"Original Developer"}],"publicationCount":2053,"therapeuticAreas":["Infectious Disease"],"biosimilarFilings":[],"originalDeveloper":"PureTek Corporation","recentPublications":[{"date":"2026 Mar 19","pmid":"41900452","title":"Advancing HIV Diagnostics: Comparative Evaluation of Multisure HIV-1/2 Rapid Confirmatory Test Against Geenius and Traditional Reference Assays Within a CDC-Aligned Diagnostic Framework.","journal":"Microorganisms"},{"date":"2026 Mar 11","pmid":"41897563","title":"Evaluation of Flu A/B, SARS-CoV-2, and RSV Antigen Combo Rapid Test in Hospitalized Children Under Two Years of Age.","journal":"Diagnostics (Basel, Switzerland)"},{"date":"2026 Mar 26","pmid":"41895288","title":"Immunogenic tumor cell death and T-cell-derived IFN-γ elicit tumoricidal macrophages to potentiate OX40 immunotherapy.","journal":"Cell reports. Medicine"},{"date":"2026 Mar 19","pmid":"41891001","title":"Prenatal exposure to SARS-CoV-2, early relational health, and child socio-emotional functioning in the first 6 months.","journal":"medRxiv : the preprint server for health sciences"},{"date":"2026 Apr","pmid":"41867287","title":"Comparative Analysis of Radiation Dose in Advanced X-Ray Mammographic Modalities and Evaluation of Potential Influencing Factors.","journal":"The Indian journal of radiology & imaging"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"PureTek Corporation","companyId":"puretek-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:14:44.386733+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}